Tenaya Therapeutics (TNYA) said Monday that preclinical data for TN-201, its gene therapy candidate for myosin-binding protein C3-associated hypertrophic cardiomyopathy, showed improved heart function.
Published preclinical data also showed extended survival and lower cardiac biomarkers associated with fibrosis and heart failure, the company said.
A mouse surrogate of TN-201 was tested against vehicle in a model that mimics severe disease in humans, Tenaya said.
The company said the results, which were dose-dependent and lasted 20 months after treatment, support its clinical development plan for TN-201. Tenaya is conducting a phase 1b/2 clinical trial to assess TN-201 as a potential treatment for myosin-binding protein C3-associated hypertrophic cardiomyopathy.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。